Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Everolimus

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 263,802Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Breckenridge Gets FDA Nod For Everolimus Oral Suspension
    Breckenridge Gets FDA Nod For Everolimus Oral Suspension

    29 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/breckenridge-announces-final-fda-approval-for-everolimus-tablets-for-oral-suspension-ab-rated-to-afinitor-disperz-302363514.html

    PR NEWSWIRE
    29 Jan 2025
    Share Share
    Amneal Pharma`s Generics Everolimus Receives Approval in US
    Amneal Pharma`s Generics Everolimus Receives Approval in US

    10 Jan 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218863

    FDA
    10 Jan 2025
    Share Share
    Upsher-Smith Selects PANTHERx Rare For Distribution Of TORPENZ
    Upsher-Smith Selects PANTHERx Rare For Distribution Of TORPENZ

    20 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/upsher-smith-laboratories-llc-selects-pantherx-rare-for-the-distribution-of-torpenz-everolimus-tablets-302226487.html

    PR NEWSWIRE
    20 Aug 2024
    Share Share
    Upsher-Smith Launches TORPENZ™ Tablets For Rare Diseases
    Upsher-Smith Launches TORPENZ™ Tablets For Rare Diseases

    05 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/upsher-smith-expands-rare-disease-portfolio-with-launch-of-torpenz-everolimus-tablets-302214621.html

    PR NEWSWIRE
    05 Aug 2024
    Share Share
    Merck’s WELIREG Improved Objective Response Rates Versus Everolimus in RCC
    Merck’s WELIREG Improved Objective Response Rates Versus Everolimus in RCC

    21 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231021045639/en

    BUSINESSWIRE
    21 Oct 2023
    Share Share
    Par Pharm`s Generic Everolimus Receives Approval in US
    Par Pharm`s Generic Everolimus Receives Approval in US

    22 Oct 2021

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205775

    FDA
    22 Oct 2021
    Share Share